文献速递急性肾损伤慢性肾脏病

端粒再帽基因治疗改善4型心肾综合征

Telomere recapping via gene therapy as a beneficial strategy for cardio-renal syndrome type 4.
PubMed 文献 · Kidney Int · 2026-02-18

本研究探讨端粒缩短在4型心肾综合征(CRS4)中的作用,并开发AAV9基因治疗JV101过表达无催化活性的人端粒酶逆转录酶(modhTERT)。在两种CRS4小鼠模型和hiPSC-CMs中,modhTERT再帽心肌端粒,逆转心脏功能障碍、肥厚、纤维化及线粒体功能异常,且效果持久;β受体阻滞剂仅延缓心衰进展。JV101还改善CKD小鼠肾功能(血尿素氮)。

要点

  • modhTERT基因治疗可再帽心肌端粒,逆转CRS4小鼠心脏功能障碍。
  • JV101改善CKD小鼠肾功能(血尿素氮水平)。
  • β受体阻滞剂仅延缓心衰进展,未实现功能逆转。

核心结论

  • 端粒再帽基因治疗(JV101)为治疗CRS4提供概念验证证据。

研究设计与样本

  • 工程化AAV9基因治疗JV101,心脏肌钙蛋白T启动子控制过表达modhTERT。
  • 使用两种CRS4小鼠模型(5/6肾切除和血管紧张素II-高盐-单肾切除)及hiPSC-CMs进行体内外评估。

主要发现

  • modhTERT再帽心肌端粒,逆转两种CRS4小鼠模型的心脏功能障碍、肥厚、纤维化及线粒体功能异常。
  • modhTERT逆转心脏功能障碍的效果长期且持久,而β受体阻滞剂仅延缓心衰进展。
  • JV101改善CKD小鼠肾功能(以血尿素氮水平衡量)。
  • hiPSC-CMs中modhTERT结合心肌端粒末端,阻止端粒进一步缩短并逆转收缩功能障碍。
  • 小鼠心肌细胞转录组分析显示modhTERT逆转线粒体代谢相关基因的抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardio-renal syndrome type 4 (CRS4) is defined as heart failure driven by chronic kidney disease (CKD). Cardiovascular mortality is the leading cause of death in patients with advanced CKD with current medical treatments exhibiting limited efficacy. Short leukocyte telomere lengths in such patients are correlated with increased mortality, particularly cardiovascular mortality. Here, we examined telomere shortening in mouse and human cardiomyocyte models of CRS4 and its potential protective role by overexpression of telomerase reverse transcriptase. METHODS: We engineered an adeno-associated virus 9 (AAV9) gene therapy JV101, which overexpressed catalytically inactive and nuclear localized human telomerase reverse transcriptase (modhTERT) under cardiac troponin T promoter control. Both in vivo and in vitro models were utilized to conduct a comprehensive evaluation of the therapeutic effects of modhTERT on CRS4. RESULTS: Overexpression of modhTERT recapped myocardial telomeres and reversed cardiac dysfunction, hypertrophy and fibrosis, and mitochondrial dysfunction in two CRS4 mouse models: 5/6 nephrectomy and Angiotensin II - high salt - uninephrectomy. The reversal of cardiac dysfunction by modhTERT was both long-term and persistent. In contrast, beta-blocker administration merely delayed the progression of heart failure in these models, without achieving functional reversal. Surprisingly, JV101 ameliorated kidney function as measured by blood urea nitrogen levels in CKD murine models. Experiments in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) demonstrated that modhTERT bound to myocardial telomeric ends. Transcriptomic analysis of isolated mouse cardiomyocytes revealed that modhTERT reversed differentially repressed genes that were highly enriched in mitochondrial metabolism. Coculture of hiPSC-CMs with serum from hemodialysis patients or indoxyl sulfate toxin induced myocardial contractile dysfunction. Overexpression of modhTERT also blocked further telomere shortening and reversed contractile dysfunction in hiPSC-CMs. CONCLUSIONS: Our results provide proof-of-concept evidence for treating CRS4 by telomere recapping gene therapy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Xie D, Wang C, Wan X, et al. Telomere recapping via gene therapy as a beneficial strategy for cardio-renal syndrome type 4. Kidney Int. 2026. PMID: 41720267. doi:10.1016/j.kint.2026.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。